Percodan®, or Tylox® (from 9.7 million to 10.8 million); OxyContin® (from 1.9 million to 2.8 million); methadone (from 0.9 million to 1.2 million); and Ultram® (from 52,000 to 186,000). The abuse for non-medical purposes of prescription drugs is largely an activity of younger White people, but the location of such use seems to be spreading throughout suburban and rural America with greater penetration into non-White racial/ethnic populations. Furthermore, over all the drug categories (opiates, sedatives/tranquilizers, and stimulants), although White males are more likely than other groups to abuse prescription drugs, recent increases in past-month use of any prescription drug occurred among females and Hispanics, and among unemployed persons. Adults age 18 to 25 are more likely than persons in other age groups to begin abusing prescription drugs, but past-year dependence-level abuse of any prescription drug increased for the 12-17 group while falling for individuals 18 and older. A particularly troubling finding is the increasing prevalence in abuse of many prescription drugs by adolescents and younger adults.
In California, several regional differences in prescription drug abuse are apparent from limited data and from anecdotal reports, but comprehensive data are lacking for many of the prescription drug phenomena. Extrapolations from national estimates of prevalence can be made to recognize that the State suffers at least the equivalent of 12% of the nation's drug problems, based on the fact that California's population is more than 12% of the nation's. Prescription drugs comprise a small proportion of all treatment admissions, but play a more substantial role in drug-related emergency department episodes and mortality data. The consequences of prescription drug abuse are considerable: by the end of 2002, emergency department mentions of benzodiazepines and opiate pain relievers were about as frequent as mentions of heroin or marijuana but ranked below cocaine and alcohol.
A primary implication of this report on prescription drugs is the recognition that preventing and treating the related problems will require a far better understanding of their extent and nature beyond what can be empirically supported by current data collection and dissemination efforts. Improvements to local and regional efforts to gather and analyze information on prescription drug abuse will be necessary first steps toward effectively addressing the growing problem of prescription drug abuse in California.
INTRODUCTION AND OVERVIEW

RATIONALE FOR THE REPORT ON PRESCRIPTION DRUG ABUSE
Abuse of prescription drugs in recent years has elicited increasing concern among policymakers, treatment providers, law enforcement personnel, school administrators, healthcare providers, parents, and researchers. "Misuse" of prescribed medications (i.e., incorrect dosing, noncompliance with dosing instructions, inadvertent mixing of incompatible drugs, accidental over/under medication, etc.) has been a longstanding problem; however, the focus of this report is the purposeful use of such drugs for non-medical reasons to achieve intoxication, which is an escalating problem across the country, especially among young people.
In California, which typically leads the nation in setting trends, prescription drug abuse occurs across all demographic and socioeconomic categories, as evident in pertinent databases. None of the existing databases offers a comprehensive, up-todate depiction of the full extent and nature of prescription drug problems, however, that would be sufficient to empirically support an accurate understanding of the situation in California. Thus, the California Department of Alcohol and Drug Programs (ADP) requested a report based on the available data to assess prescription drug abuse and its consequences.
The generally expanding prevalence and growing negative consequences of prescription drug abuse may be attributed to many factors, including the proliferation of medications for conditions such as chronic pain, insomnia, anxiety, attention-deficit hyperactivity disorder (ADHD), insomnia, narcolepsy, psychosis, and other acute and chronic ailments treated by potentially abusable drugs with psychoactive effects. The burgeoning population of elderly suffering health conditions treated by medications with psychoactive effects is pronounced in California and other states with large populations of elderly (e.g., Florida and Arizona). Prescription drugs have become more readily accessible to adolescents and young adults via "doctor shopping," pharmacy/hospital thefts, prescription forgery, unscrupulous physicians, importation from border and Internet pharmacies, and criminal diversion at wholesale levels. In some cases, use of illegally obtained prescription drugs, often in combination with alcohol or "street" drugs, displaces traditional preference for the illicit street drugs.
The consequences associated with abuse of prescription drugs are as dire as those of street drugs like heroin, cocaine, and methamphetamine: dependence, overdose-related death, compromised physical and mental health, family disruption, degraded economic activity and scholastic achievement, criminal activity, incarceration, and burdens on the health care system and criminal justice system. In spite of the growing prevalence of prescription drug abuse and increasingly evident consequences (including among high-profile public figures such as Rush Limbaugh and Michael Jackson), there have been insufficient efforts to assess and clearly delineate the associated patterns and consequences through modifications to large-scale and local data collection techniques. The resultant lack of comprehensive information on the issues has obscured awareness of the problems and has hindered development of strategies to address them.
Developing targeted strategies for prevention and treatment of prescription drug abuse requires much greater understanding of the patterns and consequences of the problem than is currently available in the extant databases. This report offers a summary view of prescription drug abuse based on the most current databases at the time of preparation (Spring 2005) . Notably, the data are incomplete for many regions and metropolitan areas across the country and in California. Furthermore, the structure of survey instruments and occasionally inconsistent administration and reporting constrain confidence in any overview based on discrete sources. Thus, this report attempts to weave together findings from the available data sources to produce a useful depiction of prescription drug abuse problems and related issues. Following discussion of the prevalence and consequences of prescription drug abuse in the nation and in California, concluding remarks offer suggestions on improvements to data collection and dissemination efforts, particularly in California, that would better serve the stakeholders involved in identifying and addressing prescription drug abuse problems.
THE WIDELY ABUSED PRESCRIPTION DRUGS
The categories of prescription drugs most widely used as illicit intoxicants and broadly recorded in many of the pertinent databases are: opiates, sedatives/ tranquilizers, and stimulants. This report focuses on the prominent prescription drugs in these three categories most widely abused for non-medical purposes of achieving psychoactive effects. The discussion excludes the medical "misuse" of prescribed medications (i.e., incorrect dosing, noncompliance with dosing instructions, inadvertent mixing of incompatible drugs, accidental over/under medication, etc.). drug-e.g., methadone, hydrocodone-is used) .
Opiates
This category includes opiates (other than heroin) such as codeine, hydrocodone (Vicodin®, Lortab®, Lorcet®, Tussionex®) , oxycodone (OxyContin®, Percodan®, Percocet-5®, Tylox®), d-propoxyphene (Darvon®), hydromorphone (Dilaudid®) , morphine, meperidine (Demerol®) , methadone (Dolophine®), and fentanyl (Duragesic®, Actiq®). In recent years, data have documented increasing production, sales, and illicit diversion of these drugs and increasing numbers of adverse events, as well as patterns of abuse by young adults and by persons in non-urban areas. The use of opiates for non-medical purposes can lead to potential consequences similar to those of the street opiates (heroin and opium), including dependence, overdose death, criminal activity, and drug-related accidents and incidents leading to morbidity and mortality.
Sedatives and Tranquilizers
This category includes barbiturate-type sedatives such as phenobarbital and secobarbital (Nembutal®, Seconal®, Tuinal®), non-barbiturate sedatives such as methaqualone (Sopor®, Quaalude®), and tranquilizers and antianxiolytics such as 
Stimulants
Though traditionally associated with fewer mortal consequences than attributable to the opiates and sedatives, the prescription stimulants are widely abused for non-medical purposes and are implicated in injury, morbidity, and death. Stimulants such as methylphenidate (Ritalin®, used to treat ADHD) have high abuse potential, and stimulant abuse rapidly escalating to dependence is common. In addition to taking prescription stimulants for their psychoactive (intoxicating) effects, people seeking performance enhancement or weight loss also abuse prescription stimulants such as dextroamphetamine (Dexedrine®, Benzedrine®, prescribed for narcolepsy), sibutramine hydrochloride (Meridia®, for depression, asthma), phentermine (Fastin®, for obesity), and methamphetamine hydrochloride (Desoxyn®, Methedrine® for ADHD and obesity) in addition to or in place of illegally produced amphetamine/methamphetamine.
PRIMARY DATA SOURCES
Data from a number of sources has been evaluated to identify trends and patterns in the abuse of prescription drugs. The data are arranged to put together a picture of who tends to use which drugs, the trends in use, and the medical and psychological consequences of prescription drug abuse. The following data sources are discussed in detail in each drug section. emergency department (ED) data and mortality data from medical examiners/coroners (ME/Cs). DAWN accepts reports of ED episodes involving the non-medical use of legal drugs (which can involve the deliberate abuse of prescribed or legally obtained over-the-counter medications or pharmaceuticals diverted for abuse) and drug-related deaths in which prescription and over-the-counter pharmaceuticals were recorded.
In calendar year 2003, the DAWN system underwent a major overhaul, and essentially every aspect of DAWN changed. To date, the only estimates to be released from the "new" DAWN ED system are preliminary, and cannot be aggregated or compared across metropolitan areas. To allow for comparisons across California metropolitan areas, final estimates and rates based on "old" DAWN ED data collected in 2002 will be presented throughout the paper.
Unlike the ED component, the ME component is not a sample and it does not provide statistical estimates for the nation as a whole; it simply collects data voluntarily reported by interested medical examiners. The DAWN mortality data presented throughout the paper is drawn from the "new DAWN" data collection system and Opiates. The 2003 NSDUH findings showed that an estimated 4.7 million persons, corresponding to about 2% of the population age 12 or older, were current (i.e., past-month) users of opiate pain relievers taken non-medically. There was a significant increase in non-medical use of pain relievers between 2002 and 2003 across the country: at some time in their lives, 31.2 million Americans had used pain relievers for non-medical purposes (up from 29.6 million). Past-year use increased from 11 million to 11.7 million. Opiate pain medications with statistically significant increases in abuse at some point in the users' lifetime were Vicodin®, Lortab®, or Lorcet® (from 13.1 million to 15.7 million); Percocet®, Percodan®, or Tylox® (from 9.7 million to 10.8 million); hydrocodone (distinct from Vicodin and other tradenamed versions (from 4.5 to 5.7 million), OxyContin® (from 1.9 million to 2.8 million); methadone (from 0.9 million to 1.2 million); and Ultram® (from 52,000 to 186,000). Among past-year users of prescription opiates, 12.2% used at dependence or abuse level per DSM IV criteria. likely than other racial/ethnic and age groups to abuse prescription drugs, though increases in past-month abuse of a prescription drug occurred among females, Hispanics (from 844,000 to 887,000), and unemployed persons. Adults age 18 to 25 are more likely than persons in other age groups to begin abusing prescription drugs, but past-year use of any prescription drug at dependence-level increased, from 189,000 to 222, 000, for the 12-17 age group, and from 695,000 to 743,000, for the 26 and older age group. benzodiazepines, but the greatest increase was for patients age 18 and 19. In 1995, the rate was higher for female patients than for male patients (37 v. 23 visits per 100,000); however, by 2002, there was no statistical difference between female and male patients mentioned in ED cases of prescription drug problems.
Sedatives and
Stimulants. Whites are more likely than other racial or ethnic groups to abuse prescription stimulants, and many people who abuse these drugs also have psychiatric disorders. Between the ages of 12 and 17, girls are more likely than boys to begin prescription drug abuse and are more likely to abuse stimulants and sedatives. Use was stable among the 12-25 age group but had declined in the 26 and older group from 2002 to 2003. Besides Whites (10.7%), Native Americans/ Alaska Natives (10.2%) and Native Hawaiians/ Pacific islanders (8.3%) had the highest rates of any stimulant use in their lifetime and Hispanics (5%), Asians (2.8%), and Blacks (2.7%) had the lowest rates. Notably, use of Ritalin had increased from 1.7 to 1.8 million in the 18-25 age group but had decreased significantly from 2.3 to 1.8 million among those older than 26, who also accounted for the vast majority of Desoxyn/Methedrine and methamphetamine users. Use of diet pills (e.g., Benzedrine, Biphetamine, Fastin, or Phentermine) was estimated to be declining across age groups.
CONSEQUENCES
Information on admissions to treatment programs and on emergency department (ED) mentions and deaths involving prescription drugs comes from two nationwide data sources: the Treatment Episode Data Set (TEDS) and the Drug Abuse Warning Network (DAWN).
Emergency Department Mentions
In 2002, non-medical use of prescription medications (i.e., psychotherapeutics, CNS agents, respiratory agents, cardiovascular agents, and other substances) antianxiety medications) and analgesics (pain relievers) collectively accounted for nearly 44% of all ED drug abuse mentions. Of those, a significant proportion of mentions could be attributed specifically to opiates and benzodiazepines.
Opiates. Narcotic analgesic/combinations were the most frequently mentioned type of analgesic, comprising 62% of all mentioned analgesics. In 2002, there were nearly 120,000 non-fatal cases of narcotic analgesic/combinations in ED mentions. Of Opiates/Opioids. In addition to including heroin and morphine, the "opiates/opioids" category in the DAWN mortality data include prescription pain relievers, methadone, and buprenorphine. In 2003, methadone was reported in more than 25% of deaths involving opiates/opioids in 12 of the 32 metropolitan areas and 3 of the 6 states. Methadone was typically not the only drug involved in these deaths.
Hydrocodone was reported in more than 25% of deaths involving opiates/opioids in Birmingham, AL, Houston, TX, New Orleans, LA, and San Francisco, CA. And oxycodone was reported in more than 25% of opiate/opioid deaths in 4 of the 32 metropolitan areas, and in 2 of the 6 states. 
REGIONAL TRENDS (CALIFORNIA AND CALIFORNIA LOCALES) IN PREVALENCE, DEMOGRAPHICS, AND CONSEQUENCES OF PRESCRIPTION DRUG ABUSE
In addition to the databases that can be used to directly and indirectly assess nationwide prescription drug abuse (e.g., SAMHSA, DAWN, etc.), information on the states and regions of states can be gleaned from other sources, particularly NIDA's Community Epidemiological Workgroup (CEWG), which meets twice yearly to present information on drug abuse for 21 major U.S. metropolitan areas (including Los Angeles, San Diego, and San Francisco). CEWG supplements data with qualitative information from ethnographic research, focus groups, and other community-based sources to achieve broad assessments of drug abuse conditions in defined regions.
PREVALENCE
The NSDUH estimated that past-month use of any illicit substance excluding marijuana was 1,122,000 individuals over 18 in California. Data show that any use of prescription drugs escalated in SAMHSA's "Pacific" Division reporting area (Alaska, California, Hawaii, Oregon, Washington): lifetime use increased from just under 8.9 million in 2002 to almost 9 million, and past-year use increased from almost 2.7 million to more than 2.8 million, with more significant escalation in past-month use from almost 
DEMOGRAPHICS
Admissions to treatment for prescription opiates were typically male (60%), White non-Hispanic (74%), and 36 to 50 years old (52% 
CONSEQUENCES
The DAWN emergency department coverage in California included 80 hospitals in the State's three largest metropolitan areas: Los Angeles, San Diego, and San
Francisco. With regard to local drug-related death information, Los Angeles has not participated in the DAWN mortality system since 2000. Therefore, no Los Angeles drugrelated death data will be included in the discussion. Information on treatment admissions for California is from the California Alcohol and Drug Data System (CADDS).
Emergency Department Mentions
When looking at 2002 DAWN data pertaining to population-based rates of prescription drug mentions, San Diego and San Francisco had rates that were similar to U.S. rates, whereas rates in Los Angeles were lower than the national average. The national averages for narcotic analgesics/combinations, benzodiazepines, and CNS stimulants were 41 per 100,000 population, 46 per 100,000, and 1 per 100,000, respectively. For narcotic analgesics/combinations, San Diego led the state with 45 mentions per 100,000 population, followed by San Francisco (42 per 100,000), and Los Angeles (28 per 100,000). For benzodiazepines, San Francisco led with 52 mentions per 100,000, followed closely by San Diego (46 per 100,000), and more distantly by Los Angeles (28 per 100,000). And among CNS stimulants, all three metropolitan areas had rates ranging from 0-1 per 100,000.
Deaths
San Diego-Carlsbad-San Marcos and San Francisco-Oakland-Fremont were the two California metropolitan areas that provided drug-related death data to the DAWN system in 2003.
In the San Diego metropolitan area (covering more than 3 million people), were implicated in 15 drug misuse deaths and 4 suicide deaths. Benzodiazepines were mentioned in 17 drug misuse deaths, and miscellaneous anxiolytics, sedatives, and hypnotics were mentioned in 6 drug misuse deaths and 5 suicide deaths.
Treatment Admissions
The CADDS database provides information on treatment admissions across the State. In 2003, there were 3,486 admissions for opiates other than heroin (48% female, 76% White, 11% Latino, and 54% occurring among those age 31 to 50). There were 372 admissions for sedatives (50% female, 81% White, and 12% Hispanic), 296 for tranquilizers (60% female, 62% White, 22% Hispanic), and 130 for prescription stimulants (notably, 20% for ages 12-17 and another 45% occurring among those age 18-35, 31% Hispanic and 49% White).
In 
SPECIFIC POPULATIONS AND SPECIAL TOPICS PRESCRIPTION DRUG ABUSE AMONG ADOLESCENTS
The 2003 increase for young adults, however (Johnston et al., 2004a (Johnston et al., , 2004b indicate that among a representative sample of children in private and public schools in California, there were decreases in tobacco, drug, and alcohol use by students in grades 7, 9 and 11 during 2003 (WestEd, 2004 . Excluding illegal drugs, marijuana, inhalants, and alcohol (thus presumably referring primarily to prescription drugs), the percentage of students responding positive for any use of "other" intoxicants four or more times in their lifetime was 3% for 9 th graders and 5% for 11 th graders. To put things into perspective, lifetime use (of four or more times) of methamphetamine among 9 th and 11 th graders was 1% and 4%, respectively; use of ecstasy was 1% and 2%, respectively; and use of inhalants was 3% and 4%, respectively.
In terms of past six month use of specific categories of prescription drugs among secondary school students in California (WestEd, 2005), 1.5% of the state's 9 th graders and 2.4% of 11 th graders reported use in the past six months of barbiturates/sedatives.
Past-six-month use of tranquilizers was slightly more common: 2.7% of 9 th graders and 5.4% of 11 th graders reported tranquilizer use in the past six months.
PRESCRIPTION DRUG ABUSE AMONG THE ELDERLY
Most problems involving prescription drugs and the elderly are from "misuse" rather than non-medical abuse of medications for purposes of achieving psychoactive effects (i.e., intoxication); as noted earlier, such misuse is not the focus of this report.
Drugs typically used and abused by elderly include sedatives, tranquilizers, and analgesics. In some cases, however, non-medical abuse occurs among the elderly.
Reports of abuse of prescription medications by elderly persons are rare in most data collection efforts. Diagnostic criteria based on tolerance and ability to discharge responsibilities (per DSM IV, for example) are not applicable to older users as the issues are not pertinent in many cases (Blow, 1999) .
Still, NSDUH data indicate the presence of some abuse of medications by elderly: 3.9% of those 55 years and older report past-month use of prescription drugs for non-medical purposes. Of the 40,044 recorded suicide attempts among DAWN ED episodes, 2,518 persons were over age 55, and were mostly White females; more than 3% of the people seeking detox from drugs in EDs were older than 55. 
ABUSE OF STEROIDS
A problem with growing consequences among young people is that of steroids.
Anabolic steroids are available only by prescription to treat conditions such as delayed puberty, and some types of impotence, and emaciation in patients with AIDS and other diseases. Abuse of anabolic steroids, however, can lead to serious health problems, some irreversible. Anabolic steroids are taken orally or injected to enhance performance and also to improve physical appearance. which may contribute to dependence on anabolic steroids (Pope & Katz, 1988 According to NFLIS data, a total of 1,417 items were identified as anabolic steroids in 2004. Of the 14 different anabolic steroids reported in the system, the most commonly identified was testosterone (36%), followed by methandrostenolone (18%), nandrolone (12%), and stenozolol (12%). Across regions, the highest relative percentages of testosterone usewere reported in the Midwest and the South. Act, a bill to limit access to products used to make methamphetamine (Feinstein, 2005 Diversion of prescription drugs is of such concern in the San Diego area that the San Diego Police Department assigned officers to deal specifically with the problem. 
OVER-THE-COUNTER DRUGS
IMPLICATIONS AND CONCLUDING REMARKS IDENTIFYING PRESCRIPTION DRUG ABUSE PROBLEMS
It is clear from the gaps in available information that a more comprehensive picture regarding the phenomenon of prescription drug use and abuse is needed.
Prescription drug abuse is difficult to characterize for several reasons. First, there is often a lack of detailed or specific information among the standard substance abuse indicator data. Many data sources do not address prescription drug use at all; for those that do address the non-medical use of prescription medications, information is often available for broad classes of medications (e.g., stimulants, tranquilizers, opiates/opioids, etc.) but not for specific medications within each class (e.g., oxycodone, hydrocodone, diazepam, methylphenidate, etc.).
Because a local, comprehensive data collection system is not currently in place to determine the prevalence of prescription drugs among California residents, it is impossible to make definitive, high-confidence estimations of the underlying levels of use. Even treatment admissions data are lacking specificity on prescription drug abuse, limiting an estimation of the extent of prescription drug abuse as a precursor to individuals seeking help for drug problems or being remanded to treatment by the criminal justice system.
FUTURE RESEARCH AND RECOMMENDATIONS
Although increases in prescription drug use have been documented among most ethnic and age categories, there were across-the-board declines from 2002 to 2003 in the percentages of those who "needed and received treatment" for an illicit drug (which included non-medical use of prescription drugs) or alcohol problem in the past year among persons age 12 or older. Only Asians and Native Americans showed increased involvement in treatment, and together they accounted for fewer than 2% of the total admitted to treatment.
An in-depth assessment of interdiction/diversion, prevention, and treatment initiatives that have been created to address the issue of prescription drug abuse is one strategy that could be undertaken at the State level.
To help understand the problem and help inform policy, the State could create a statewide prescription drug workgroup. The purpose of such a group would be to better characterize prescription drug use and the adverse consequences associated with the abuse of such drugs, and identify specific user groups. The workgroup could be comprised of local epidemiologists and academic-based researchers, law enforcement personnel, school administrators, pharmacists/physicians, crime lab specialists/ toxicologists, substance abuse and mental health practitioners, and county agency administrators. Physicians and pharmacists, who legitimately prescribe and dispense prescriptions, are integral to such a group because they can help to explain changes in patterns of use reflecting changes in practice. Medical examiners/coroners and toxicologists can help to detect emerging issues and help to interpret the data relating to positive toxicology screens and underlying causes of death.
Another recommendation is to conduct another iteration of the California Household Substance Use Survey, which was last conducted in 1999 by the Western Consortium for Public Health (and was prepared for ADP with SAMHSA funding). The survey addressed use of tobacco, alcohol, and other drugs. Questions relating to prescription drug abuse could be added to provide California policymakers with more indepth information than is available through the state estimates of the NSDUH.
As is evidenced by this white paper, prescription drug abuse does occur among significant numbers of individuals in California and beyond. There are currently fewer prescription drug abusers than alcohol abusers and illicit drug abusers, but rapid escalation of prescription drug problems could occur, especially among some populations (e.g., adolescents) and the situation must be monitored in a more consistent, comprehensive manner to enable State-level and local-level responses in terms of prevention and treatment.
